ECSP17046657A - Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina - Google Patents

Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina

Info

Publication number
ECSP17046657A
ECSP17046657A ECIEPI201746657A ECPI201746657A ECSP17046657A EC SP17046657 A ECSP17046657 A EC SP17046657A EC IEPI201746657 A ECIEPI201746657 A EC IEPI201746657A EC PI201746657 A ECPI201746657 A EC PI201746657A EC SP17046657 A ECSP17046657 A EC SP17046657A
Authority
EC
Ecuador
Prior art keywords
trioxacarcin
analogues
preparation
total synthesis
synthesis
Prior art date
Application number
ECIEPI201746657A
Other languages
English (en)
Inventor
LLC Lub-Line
Quan Cai
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of ECSP17046657A publication Critical patent/ECSP17046657A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En un aspecto, la presente invención proporciona derivados novedosos de análogos de trioxacarina de la fórmula (I) (I) en donde las variables son como se define anteriormente. La aplicación también proporciona composiciones, métodos de tratamiento, y métodos de síntesis de los mismos.
ECIEPI201746657A 2014-12-19 2017-07-19 Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina ECSP17046657A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094662P 2014-12-19 2014-12-19
US201562186128P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
ECSP17046657A true ECSP17046657A (es) 2019-03-29

Family

ID=56127867

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201746657A ECSP17046657A (es) 2014-12-19 2017-07-19 Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina

Country Status (23)

Country Link
US (1) US10899773B2 (es)
EP (1) EP3233877A4 (es)
JP (1) JP2017537968A (es)
KR (1) KR20170122718A (es)
CN (1) CN107250144A (es)
AU (1) AU2015364347A1 (es)
BR (1) BR112017013194A2 (es)
CA (1) CA2970955A1 (es)
CL (1) CL2017001599A1 (es)
CO (1) CO2017007074A2 (es)
CR (1) CR20170331A (es)
DO (1) DOP2017000144A (es)
EA (1) EA201791388A1 (es)
EC (1) ECSP17046657A (es)
GT (1) GT201700139A (es)
HK (1) HK1243422A1 (es)
IL (1) IL252947A0 (es)
MA (1) MA41216A (es)
MX (1) MX2017008162A (es)
PE (1) PE20171787A1 (es)
PH (1) PH12017501147A1 (es)
SG (1) SG11201704935XA (es)
WO (1) WO2016100833A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210230178A1 (en) * 2017-08-17 2021-07-29 William Marsh Rice University Trioxacarcin analogs and dimers as potent anticancer agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815995A (ja) 1981-07-22 1983-01-29 Kyowa Hakko Kogyo Co Ltd Dc−45−a↓1およびdc−45−a↓2ならびにそれらの製造法
EP0157203A3 (en) 1984-04-04 1986-10-01 American Cyanamid Company Antitumor agents ll-d49194 alpha 1, ll-d49194 beta, ll-d49194 beta 2, ll-d49194 upsilon, ll-d49194 delta, ll-d49194 epsilon, ll-d49194 zeta, and ll-d49194 eta
JPS63135389A (ja) 1986-11-26 1988-06-07 Kyowa Hakko Kogyo Co Ltd Dc−45類の誘導体
EP2550285B1 (en) 2010-03-22 2017-07-19 President and Fellows of Harvard College Trioxacarcins and uses thereof
WO2014082065A1 (en) 2012-11-26 2014-05-30 President And Fellows Of Harvard College Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof

Also Published As

Publication number Publication date
MA41216A (fr) 2017-10-24
EP3233877A4 (en) 2018-10-17
US20190023717A1 (en) 2019-01-24
IL252947A0 (en) 2017-08-31
EP3233877A2 (en) 2017-10-25
CA2970955A1 (en) 2016-06-23
CR20170331A (es) 2017-11-17
BR112017013194A2 (pt) 2018-01-02
CN107250144A (zh) 2017-10-13
HK1243422A1 (zh) 2018-07-13
MX2017008162A (es) 2018-03-06
AU2015364347A1 (en) 2017-07-13
DOP2017000144A (es) 2017-09-29
JP2017537968A (ja) 2017-12-21
PH12017501147A1 (en) 2018-03-05
SG11201704935XA (en) 2017-07-28
WO2016100833A3 (en) 2017-01-05
PE20171787A1 (es) 2017-12-28
WO2016100833A2 (en) 2016-06-23
CO2017007074A2 (es) 2017-10-20
CL2017001599A1 (es) 2018-11-09
US10899773B2 (en) 2021-01-26
KR20170122718A (ko) 2017-11-06
EA201791388A1 (ru) 2017-11-30
GT201700139A (es) 2018-10-24

Similar Documents

Publication Publication Date Title
CO2017013709A2 (es) Lactamas bicíclicas.
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
CO7400867A2 (es) Modificador del sabor dulce
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
GT201700190A (es) Desacetoxitubulisina h y análogos de esta
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20170008A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
SV2017005381A (es) Compuestos de imidazopiridazina
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
CR20160448A (es) Nuevos derivados de piridina
DOP2016000293A (es) Derivados de diheterociclo enlazado a cicloalquilo
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
UY36169A (es) Nuevas pirazolil-triazolil-piridinas como agentes plaguicidas
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
ECSP17046657A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
EA201591449A1 (ru) Способы получения противораковых композиций
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.